Nudelman Abraham
Chemistry Department, Bar Ilan University, Ramat Gan 52900, Israel.
Curr Med Chem. 2025;32(23):4603-4656. doi: 10.2174/0109298673305662240702071354.
This review, focused on hybrid drugs, is the third in a series of reviews, where the first two reviews dealt with a) dimeric drugs, b) mutual prodrugs - codrugs. The compounds designated as hybrids are comprised of two (and sometimes three) biologically active entities, linked by metabolically stable bridges. In some cases, one of the two components of the hybrids serves as a carrier for the second component, and most frequently, the components elicit their individual biological properties, which are commonly synergistic or complementary. Due to the very large number of publications dealing with hybrid drugs, the present review is restricted to hybrids acting in the central nervous system. Future reviews will cover fields such as antimicrobial, anticancer, and antiviral hybrids, and cardiovascular active hybrids. The selected articles reviewed herein were published between the years 2000-2022 with partial coverage of the year 2023.
本综述聚焦于杂合药物，是系列综述中的第三篇，前两篇综述分别涉及：a）二聚体药物，b）相互前药——共前药。被指定为杂合的化合物由两个（有时是三个）生物活性实体组成，通过代谢稳定的桥连基团相连。在某些情况下，杂合药物的两个组分之一充当另一个组分的载体，并且在大多数情况下，这些组分发挥其各自的生物学特性，这些特性通常是协同或互补的。由于涉及杂合药物的出版物数量众多，本综述仅限于作用于中枢神经系统的杂合药物。未来的综述将涵盖抗菌、抗癌、抗病毒杂合药物以及心血管活性杂合药物等领域。本文所综述的选定文章发表于2000年至2022年之间，部分涵盖了2023年。
